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Abstract
Plasmodium species are the causative agents of malaria, the most devastating insect-borne parasite of human populations.
Finding and developing new drugs for malaria treatment and prevention is the goal of much research. Angiotensins I and II
(ang I and ang II) and six synthetic related peptides designated Vaniceres 1-6 (VC1-VC6) were assayed in vivo and in vitro for
their effects on the development of the avian parasite, Plasmodium gallinaceum. Ang II and VC5 injected into the thoraces of
the insects reduced mean intensities of infection in the mosquito salivary glands by 88% and 76%, respectively. Although
the mechanism(s) of action is not completely understood, we have demonstrated that these peptides disrupt selectively the
P.gallinaceum cell membrane. Additionally, incubation in vitro of sporozoites with VC5 reduced the infectivity of the
parasites to their vertebrate host. VC5 has no observable agonist effects on vertebrates, and this makes it a promising drug
for malaria prevention and chemotherapy.
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Introduction
Malaria remains one of the world’s most deadly diseases.
However, efforts to control this disease are hampered by drug
resistance in parasites, insecticide resistance in mosquitoes, and the
lack of an effective vaccine [1]. Malaria parasites (Plasmodium sp)
have an intricate and complex life cycle in vertebrate (interme-
diate) and invertebrate (definitive) hosts, and the multiple
developmental forms of Plasmodium species are potential targets
of distinct antiparasite molecules. For example, the mosquito-stage
parasites can be disrupted by natural and engineered peptides,
such as the antimicrobial peptides (AMP) cecropin, magainin,
defensin, scorpine and cecropin-like peptides [2–6]. However, all
the AMPs tested thus far fall short of the requirements for an
effective anti-plasmodial molecule since they require high
concentrations both in vivo and in vitro to be effective. These
results support the search for alternative molecules, including
novel peptides with lower effective doses.
Antimicrobial peptides kill bacteria by interfering with metab-
olism, targeting cytoplasmic components and disrupting mem-
branes [7]. Lipid composition of the target cell membrane is a
determining factor in the activity and selectively of AMPs for
avoiding damage to host cells [8,9]. Peptides with parasiticidal
effects on sporozoites could be utilized to target parasites within
their vector mosquitoes. These same peptides, being harmless to
vertebrate hosts, would have a broader application in malaria
prophylaxis by targeting circulating sporozoites and preventing the
establishment of infection. With this aim, we used the avian
malaria parasite, Plasmodium gallinaceum, as a model system to
search for drugs with both properties: toxicity to parasites and
harmless to vertebrates and invertebrate hosts. We report here that
a synthetic angiotensin II-related, vertebrate-inactive peptide
(VC5) kills P. gallinaceum sporozoites in vitro and in vivo and discuss
possible applications of this finding in the development of novel
malaria control strategies.
Results
Ang I, ang II and VC1-VC6 peptides reduce the number of
P. gallinaceum sporozoites in salivary glands
Injection of ang II (5–60 mM) in the hemolymph of P.gallinaceum
infected Ae. aegypti reduces sporozoites accumulation in the salivary
glands and does not affect mosquito survival (Supporting
Materials, Figure S1 and Figure S2). Following this initial
observation, synthetic ang II related peptides were designed and
tested for their anti-parasite activities. Injection of 0.5 ml of
synthetic peptides VC1-VC 6, ang I and ang II (at 60 mM
concentration) in infected mosquitoes resulted in reduced numbers
of sporozoites in their salivary glands when compared with
controls injected with either PBS or ang I (Figure 1). VC1 showed
the least effect on accumulation of sporozoites, while ang II and
VC5 where the most effective reducing by 88% (p,0.0001) and
76% (p,0.001), respectively, the number of parasites compared to
control infected mosquitoes. Additionally, each peptide was tested
for its anti-sporozoite activity in three independent experiments
and only ang II and VC5 were consistently effective (p,0.005) in
reducing the number of salivary glands parasites.
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Ang I, Ang II and VC1-VC6 increase sporozoite membrane
permeability
Mature sporozoites were recovered from salivary glands and
incubated in vitro with ang II or VC peptides. Cell membrane
integrity was monitored at 10 minutes intervals by adding
propidium iodide to the treated parasite samples (Figure 2).
Sixty-four percent of the sporozoites showed nuclear fluorescence
indicative of cell damage after 10 minutes incubation with 60 mM
ang II, and 78% showed fluorescence after 30–60 minutes. VC1,
VC2, VC3, VC4 and VC6, respectively, resulted in 73%, 51%,
51%, 64% and 38%, sporozoites with fluorescent nuclei after
1 hour incubation. VC5 resulted in a kinetic profile similar to that
obtained with ang II. Incubations with 60 mM VC5 yielded 51%,
67% and 78% fluorescent sporozoites at 10, 20 and 60 minutes,
respectively. Fluorescence accumulation in the nuclei was
observed in only 47% of the sporozoites treated with 60 mM ang
I after 1 hour incubation.
Further evidence of the association of ang II and VC5 peptides
with the sporozoite cell membrane was obtained by scanning electron
microscopy (Figure 3). Sporozoites incubated with VC5 show surface
damage evidenced by cytoplasmic protrusions, and this is consistent
with the propidium iodide staining of their nuclei (Figure 2).
Parasitological evidence of inactivation of salivary gland
sporozoites by VC5
Vertebrate-infective parasites harvested from mosquito salivary
glands were incubated in vitro with VC5 and then inoculated into
chickens. Both the infection rates (15%) and the pre-patent periods
(7–21 days) were affected (Table 1). Only four of nine chickens
challenged with VC5-treated sporozoites became infected, and
those showed an increased pre-patent period, 7 to 21 days,
compared to six days post-infection in the control group. Parallel
incubations in vitro, without VC5, under identical conditions did
not diminish the infectivity of parasites, as demonstrated by the
infection of 100% of chickens challenged with these control
samples. This preliminary experiment further support that VC5
interacts with malaria parasites cell membrane indicates that this
interaction results in non-infectious sporozoites.
Agonistic activities of synthetic VC1-VC6 and ang II
In addition to applications of VC5 and ang II to target
sporozoites in the vector mosquitoes, these peptides also could be
useful to block parasite development in vertebrate hosts.
Angiotensin II is a well-known direct activator of smooth muscle
in the vasculature, constricting arteries and veins and increasing
blood pressure. Assays of ileum contraction, commonly used to
determine vasoconstriction activities, were utilized to test agonistic
activities of the peptides on guinea pig (GPI), chicken ileum (CI)
and rat uterus (RU) preparations. When compared with ang II
(100% activity), VC1 had 5%, 0% and 2.0% of agonist activity on
GPI, CI and RU, respectively (Table 2). VC2 had 10%, 0% and
2.9% of activity for GPI, CI and RU. VC3, VC4, VC5 and VC6
activities were less then 0.3%, consistent with the interpretation
that the VC1-6 peptides have low or no agonistic action.
Figure 1. Numbers of sporozoites in salivary glands of angiotensin I-, angiotensin II- or synthetic peptide-treated Ae. aegypti. At day
7 post-infection 0.5 ml of ang I (60 mM), ang II (60 mM), VC1 (60 mM), VC2 (60 mM), VC3 (60 mM), VC4 (60 mM), VC5 (60 mM), VC6 (60 mM) and PBS
(control) were microinjected intrathoracically on anesthetized Ae.aegypti. Salivary glands were dissected 24 hours after the microinjection and
sporozoites counted. Kruskal–Wallis tests indicated significant effects (p,0.0001 and p,0.001) of the peptides in the number of salivary glands
sporozoites for ang II and VC5, respectively. VC1, VC2, VC3, VC4, VC6 did not significant effect (p.0.05).
doi:10.1371/journal.pone.0003296.g001
Angiotensin II and Malaria
PLoS ONE | www.plosone.org 2 September 2008 | Volume 3 | Issue 9 | e3296
Figure 2. Effects of peptides on membrane permeability of mature sporozoites were incubated with digitonin, PBS, 60 mM of ang I,
ang II, VC1, VC2, VC3, VC4, VC5 or VC6. After defined intervals at room temperature, propidium iodide was added and the sporozoites were
examined by fluorescent microscopy. A, sporozoites in phase (left) and fluorescent (right) microscopy; B, kinetic curves of membrane fluorescence.
Results are the mean of three independent experiments, and bars represent standard errors of the mean. The data were statistical analyzed (60 min)
using Fisher’s test showing that ang II, VC1 and VC5 are significant different (p,0.02) when compared with control. On the other hand, ang I, VC2,
VC3, VC4 and VC6 are not significantly different (p.0.05).
doi:10.1371/journal.pone.0003296.g002
Angiotensin II and Malaria
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Stability and absence of hemolytic activity of ang II and
VC1-VC6
Hemolytic activity was evaluated using fresh human erythro-
cytes harvested and incubated with serial dilutions of the peptides,
and concentrations varying between 0.19–100 mM. Hemolysis was
not detected even at the higher concentrations (Table 2). Ang II
and VC1-VC6 analogue stability in blood was evaluated in non-
heat inactivated human serum, demonstrating that the peptides
were degraded within 30 minutes of incubation, as determined by
LC/ESI-MS (data not shown).The quick clearing of the molecules,
low or no agonist activity and the absence of hemolysis caused by
the peptides are indicative of their general non-toxicity to
vertebrates.
Figure 3. Scanning electron microscopy of salivary gland-derived P. gallinaceum sporozoites. Parasites were incubated with PBS (A,
control), angiotesin II (B) and VC5 (C and D). Note the smooth surface of the non-treated sporozoites (PBS-control) with the rough surface of the drug-
treated parasites (ANG II and VC5).
doi:10.1371/journal.pone.0003296.g003
Table 1. Infectivity for chicks of P. gallinaceum spzs from salivary glands after incubation with 60 mM of VC5.
Inoculum sizea Chicks nu infected/nu injected Prepatent periodb (Days)
VC5 (60 mM) 50 1/3 9
500 3/5 7, 12, 21
PBS 50 5/5 6
500 1/1 6
aThe chicks were i.v. inoculated after 1 hour incubation of spzs and VC 5 or PBS.
bPre-patent period is 6 days.
doi:10.1371/journal.pone.0003296.t001
Angiotensin II and Malaria
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Discussion
A recent worldwide trend of attention to malaria control has
come with accompanying financial support directed towards the
development of new drugs, anti malarial vaccines and alternatives
for vector population management [10]. Technical developments
such as the sequencing of the genomes of malaria parasites [11]
and the vector mosquito Anopheles gambiae [12], and the ability of
generating parasite-resistant genetically-modified mosquitoes [13]
have been heralded as keystones for the development of novel
malaria control tools. Our efforts to develop peptides with anti-
malarial activities led us to determine serendipitously that
angiotensin II affects negatively the development of malaria
parasites. Here we report our initial examination of the
mechanisms that result in such effect.
Ang II is derived from the constitutively-produced angiotensin-
ogen, a peptide of the serpin family released into the circulation
mainly by the vertebrate liver. When blood pressure decreases in
the kidneys the enzyme rennin is produced and cleaves the peptide
bond between the leucine (Leu) and the valine (Val) residues
creating the ten amino acid peptide angiotensin I (ang I). Ang I has
little biological effect and it is processed further to ang II by
removal of two of the terminal amino acid residues. Ang II plays
an endocrine role in the regulation of blood pressure, fluid and
electrolyte homeostasis. In addition, studies have shown that
numerous tissues and organs contain their own locally-generated
angiotensin products that exhibit tissue-specific activities [14].
Therefore, the biological activities of ang II preclude its utilization
as an anti-malarial drug. Modifications of the molecular structure
of ang II were then considered, and we designed six related
peptides (VC1-VC6) that were further analyzed. VC5 displayed
no agonistic effects and killed malaria sporozoites in the conditions
utilized in our experiments. The mechanism of parasite killing was
further investigated by biochemical and morphological applica-
tions. VC5 and ang II kill P. gallinaceum sporozoites by disruption of
their plasma membrane. Moreover, these peptides have no similar
effect upon vertebrate cells. The observed specificity may be
explained by the markedly different lipid compositions of
Plasmodium and vertebrate cells plasma membranes [15]. VC5 is
a promising molecule to be tested for malaria prevention and
chemotherapy.
Final Remarks
Our research shows that angiotensin-related peptides affect
malaria parasite survival. These peptides were engineered
successfully to abolish their agonist functions while retaining
parasiticidal activity, opening new research possibilities. Presently,
the design, synthesis, and biological evaluation of new analogues
are in progress in our laboratories with the ultimate goal of
generating further information on the structural requirements for
ang II analogues bioactivity and conformation. These studies focus
on bridge-length optimization and amino acid chirality that may
improve molecular stability against protease presents on plasma
and result in longer time of action. Additional research is necessary
to further characterize the mechanism of action of these peptides
to kill Plasmodium parasites and direct future efforts in drug
development that can contribute to the control of malaria.
Materials and Methods
Peptide synthesis, purification and characterization
Angiotensin II (ang II)-related peptides were synthesized by a
solid-phase method using the t-Boc strategy on a chloromethylated
resin [16], with substitutions varying from 0.5–0.8 mequiv/g. The
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following side-chain protected Boc-amino acids were employed
from Bachem Inc. (Torrance, CA): Arg(Tos), Asp(OcHex) and
(OFm), His(Tos), Lys(Fmoc) and Tyr(2-Cl-Bzl). Ang ll reagents
and solvents were of analytical grade and used from freshly opened
containers without any further purification. The Na-terminal
protections were removed with 50% TFA in methylene chloride in
the presence of 2% anisole for 20 min. Couplings were done using
2.5-fold excess of 1,3-diisopropylcarbodiimide/N-Hydroxybenzo-
triazole (DIC/HOBt) in methylene chloride-dimethylformamide
(DCM-DMF) (1:1, v/v). Both steps were monitored by the
ninhydrin test [17]. Couplings times were 1–2 h, and when
needed, recouplings of 1 h were done using 2.5-fold excess o-
benzotriazol-1-yl-N,N,N9,N9-tetramethyluronium tetrafluorobo-
rate (TBTU) in the presence of excess N-N9-diisopropylethylamine
(DIEA) in methylene chloride-1-methyl-2-pyrrolidone (DCM-
NMP) (1:1, v/v) [18]. Boc-His (Tos) DCHA (dicyclohexylammonium
salt) incorporation employed a 1.5-fold excess of TBTU in
presence of excess of diisopropylethylamine (DIPEA). Acetylations
were performed with 50% acetic anhydride in DMF for 15 min
when required. The orthogonal protection of the side chain of the
aspartic acid (OFm) and lysine (Fmoc) residues were used in order
to allow the lactam bridge formation with the peptide still attached
to the resin [19]. After washes with DCM, DMF, the OFm/Fmoc
groups were removed by 20% piperidine in DMF. The peptide-
resin was cyclized by reaction with 3.0-fold excess of benzotriazol-
l-yl-oxy-tris-(dimethylamino)phosphonium hexa-fluorophosphate
(BOP) in the presence of excess DIEA in 20% DMSO/NMP.
After washing the cyclization was repeated every 20 minutes. The
reaction was followed by the Kaiser ninhydrin test [17]. The dry
protected peptidyl-resin was exposed to anhydrous hydrogen
fluoride (HF) in the presence of 5% anisole and of 5%
dimethylsulfide for 75 min at 0uC. HF excess and scavenger were
eliminated under high vacuum. The crude peptides were
precipitated with anhydrous diethyl ether, separated from ether-
soluble by filtration, extracted from the resin with 5% acetic acid
in H2O and lyophilized. The crude lyophilized peptides were
purified in two steps (triethylammonium phosphate (TEAP)
pH = 2.25 and 0.1% TFA) by preparative Reversed Phase-High
Performance Liquid Chromatographic (RP-HPLC) on a Waters
Associates system (Model Prep 4000), using linear gradients (slope
0.33% B/min). Briefly, they were loaded on a Vydac C18
(256250 mm, 15 mm particle size, 300A˚ pore size) preparative
RP-HPLC column at a flow rate of 7.0 ml/min and eluted with
TEAP (pH = 2.25)/CH3CN), and detection at 220 nm. Selected
fractions were collected and converted to the Trifluoroacetic acid
(TFA) salt by loading on a preparative column as mentioned above
and eluted using a linear gradient (slope 0.33 or %B/min)
containing a mixture of solvents A [0.1% TFA/H2O] and B [0.1%
TFA in CH3CN/H2O (75:25)] at a flow rate of 7.0 ml/min.
Selected fractions containing the purified peptide were pooled and
lyophilized [20]. Analytical RP-HPLC was performed on a Waters
Associated system using a linear gradient of 5–95% B for 30 min,
using buffer system: A = 0.1% TFA/H2O and B = 0.1% TFA-60%
CH3CN/H2O, at 1.5 ml/min, on a Beckman C18 column
(4.66150 mm, 5 mm particle size, 300A˚ pore size) at 215 nm.
Capillary zone electrophoresis was done by using a Waters
System, model CIA (Capillary Ion Analyzer) by hydrostatic
injection in 25 seconds, utilizing Phosphate buffer pH 2.50,
l= 214 nm, silica capillary (75 mm660 cm), voltage 20 kV at
30uC. Amino acids analyses were made by the ninhydrin method
using an automatic analyzer Beckman, model System 6300.
Peptides were hydrolyzed (1 mg) using 1 ml of HCl 6 M, in the
presence of phenol 0.08 ml to 5% in water at 110uC for 72 hours
in atmosphere of N2. After hydrolysis, the material was vacuum-
concentrated and dissolved in 0.2 M sodium citrate, pH 2,2,
filtered through Millipore (pore 0,45 mm) before being injected in
the analyzer. The molar relationship of the amino acids was
established using the concentration unitary of the closest amino
acid of the average for all the residues [21]. The peptides were
analyzed on a Micromass spectrometer model TofSpec SE using
voltage = 20 KV, suppression at 500 AMU, Mode Reflectron (10
KV) and the a-ciano-4-hydroxycinnamic acid solid matrix. The
spectrometer was periodically calibrated with angiotensin I and
AII. Purified peptides were characterized (Table 2), by RP-HPLC
(Reversed-Phase Liquid Chromatography), CE (Capillary Elec-
trophoreses), AAA (Amino acid Analyses) and MS (Mass
Spectroscopy). The characterization results showed that the amino
acid proportion were in agreement with the expected values by
AAA (data not shown), purity in HPLC and CE showed to be
above 95%, and had appropriate molecular weights by mass
spectroscopy. (Table 2).
Agonistic VC5 activity to angiotensin II
Peptide agonist bioassays were performed in isolated guinea pig,
rat and chicken ilea comparison the synthetic peptides with ang II.
Male guinea pigs (weight: 200–250g) and chickens (30–40g) were
sacrificed and the terminal portions of the ileum removed and
washed several times with Tyrode solution (8 g NaCl; 0.2 g CaCl2;
0.1 g MgCl2; 0.2 g KCl; 1 g NaHCO3; 0.05 g NaHPO4 and 1g of
glucose per liter of water). After 15 minutes in nutritive solution at
room temperature, the ileum was sectioned (4.5 cm) and fixed in
the perfusion chamber with 5 ml of aerated Tyrode solution
bubbled with a gas mixture of 95% O2/5% CO2 at 3760.5uC.
Isotonic contractions were registered by a chimograph (Palmer),
under a resting load of 1g. VC5 was dissolved in H2O (1.0 mg/
ml), diluted in 0.9% NaCl and added to the perfusion chamber.
After 90 seconds, the preparation was washed with Tyrode
solution. The measurements of agonist activity were done in
triplicate.
Blood pressure assays were conducted on female rats (250–
300 g) anesthetized with a ketamine-xylazine (Ketamine 80 mg/
kg and Xylazine 8 mg/kg) solution and maintained by artificial
breathing. A catheter was inserted into the carotid artery and used
to register the blood pressure with a pressure transducer (Hewlett-
Packard, model 1280C-02), amplifier (Hewlett-Packard, model
8805B) and chart recorder (ECB, model RB102). Isotonic
solutions of the peptides were injected in the femoral vein using
a polyethylene catheter inserted (Table 2).
Hemolytic activity
Hemolytic activity was evaluated on fresh human erythrocytes
washed three times with phosphate-buffered saline (PBS: 10 mM
Na2HPO4, 1.8 mM K2-HPO4, pH 7.4, containing 140 mM NaCl
and 2.7 mM KCl) ) [22]. Serial dilutions of the peptides with
concentrations varying between 0.19–100 mM were incubated in
Eppendorf tubes with a suspension of 0.4% erythrocytes in PBS.
After 1 h at 37uC, the test tubes were centrifuged at 300g for
5 min at 5uC. Fifty microliter aliquots of the supernatants were
transferred to 96-well plates and hemolysis was monitored at
405 nm using a microtiter plate reader. Negative and positive
controls were prepared in PBS and in PBS supplemented with
0.1% SDS, respectively. Ang ll of the experiments was performed
in triplicate.
Serum stability
Twenty microliters of an aqueous peptide stock solution
(10 mg/ml) were added to 1 ml of 25% pooled non-heat
inactivated human serum in PBS and incubated at 37uC.
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Aliquots of 50 ml were added to 5 ml of TFA at time intervals
(0, 10, 20, 30, 60 and 120 minutes). The resulting mixtures
were kept at 5uC for 10 min and then centrifuged at 3006g for
5 min. Twenty microliters of the supernatants were injected in a
LC/ESI-MS equipment and the components separated using a
linear gradient of acetonitrile in acidified water (0.1% TFA) at a
flow rate of 0.4 ml/min from 5% to 95% B (0.1% TFA/60%
CH3CN/H2O) in 30 min. Peptide consumption mentored as
an area decrease under the corresponding peak in the
chromatogram allowed the evaluation of the stability of the
peptide in serum. All the experiments were performed in
triplicates.
Mosquito rearing and maintenance of the parasite life
cycle
The RED strain of Aedes aegypti is highly susceptible to P.
gallinaceum [23] and was used in all experiments. Mosquitoes were
reared using standard laboratory procedures [24].
An aliquot of frozen chicken blood infected with P. gallinaceum
strain 8A was obtained from A. Krettli (Rene´ Rachou Institute of
Research, FIOCRUZ, MG, Brazil). This sample was used to
inoculate and establish initial infections in chickens. All subsequent
infections of chickens and mosquitoes were accomplished by
feeding mosquitoes on chickens.
Mosquito injection
Each synthetic peptide was injected (0.5 ml of 60 mM) into a
group of naturally-infected mosquitoes seven days after a blood
meal, at a time when sporozoites were anticipated to be present in
the hemolymph. The same volume of PBS was injected into a
control group. Injections were performed using a finely-drawn
calibrated glass microcapillary tube to deliver the solutions into the
thorax. After 24 hours, individual pairs of salivary glands were
dissected, homogenized in 10 ml PBS, placed on a hemacytometer
and the sporozoites counted using phase-contrast microscopy. This
procedure allowed the examination of the whole salivary gland for
sporozoites [25]. All fields of the hemacytometer were examined
thoroughly in low parasites densities samples and five fields were
averaged for high parasite densities samples.
Inactivation of sporozoite infectivity
In vitro experimental treatments were performed with 50–500
sporozoites isolated from salivary glands 13 days after mosquito
infection. Parasites were mixed with synthetic peptides to final
concentration of 60 mM. After 1-hour incubation at room
temperature, the samples were injected intravenously into two-
days-old chickens. Blood smears were taken daily from each
chicken (6 to 25 days after inoculation), stained with Giemsa after
methanol fixation, and examined by light microscopy at
magnification of 1000x. The pre-patent period was calculated as
number of days between inoculation and detection of circulating
parasites in the chickens.
Effects of Angiotensin I (ang I,) Angiotensin II (ang II) and
Vaniceres 1-6 (VC1-6) on salivary gland-derived
Plasmodium gallinaceum sporozoites
Three thousand P. gallinaceum mature sporozoites were recov-
ered from salivary glands and incubated with 40 mM digitonin,
60 mM ang I, 60 mM ang II, 60 mM VC1-6 or PBS at room
temperature. Cell membrane integrity was then monitored at
10 minutes intervals by adding propidium iodide to the treated
parasites.
Scanning electron microscopy
Freshly-purified sporozoites from salivary glands were incubated
in 50 ml PBS at room temperature in the absence or presence of
60 mM ang II and 60 mM VC5. After incubation, 10 ml aliquots
were separated and fixed overnight with 2.5% glutaraldehyde in
0.1 M cacodylate buffer, pH 7.2. The glutaraldehyde-fixed
samples were rinsed three times in PBS and post-fixed in 1%
osmium tetroxide solution in 0.8% potassium ferrycianide in
0.1 M caccodylate buffer pH 7.2 for two hours, and then washed
three times in PBS. The samples were dehydrated in ethanol, dried
in critical point device with CO2 method, mounted in special
stubs, coated with platinum particles and analyzed by SEM (JEOL
JSM 5600).
Toxicity assays of VC5 in chicken
The toxic effect of VC5 was evaluated in chickens. Six animals
per cage weighing 30–40 g each were housed in groups of 10 in
our institutional animal care facility and allowed to adapt for seven
days prior to the onset of experiments. Animals were maintained
in a temperature-controlled environment (2162uC), with free
access to water and food. All experiments were carried out in
accordance with the guidelines of the Institutional Ethics Review
Committee (Cole´gio Brasileiro de Experimentac¸a˜o Animal–
COBEA) and Animal Care of the Institute of Biomedical Sciences
(Comissa˜o de e´tica em experimentac¸a˜o animal–CEEA)–University
of Sa˜o Paulo, protocol #133.
Statistical analysis
The Kruskal-Wallis test, Fisher’s Exact test, chi-square test and
Mann-Whitney U test (GraphPad InStat version 3.00 for Windows
95, GraphPad Software, San Diego California USA, www.
graphpad.com) was used to assess the statistical significance of
the differences between control and peptides injected groups.
Supporting Information
Figure S1 Survival of mosquitoes injected with different ang II
concentrations. Ae.aegypti mosquitoes (10 females) were injected
intrathoracically (0.5 ml) of ang II at 10 mM, 20 mM, 50 mM,
60 mM, 100 mM and 200 mM. After 24 hour the survival of
mosquitoes was scored. Chi-square test indicated that no
significant effects of the ang II (p.0.5) in mosquito survival for
all the experiments. Results are the mean of three independent
experiments (20 mosquitoes/group), and bars represent standard
errors of the mean.
Found at: doi:10.1371/journal.pone.0003296.s001 (0.18 MB TIF)
Figure S2 Numbers of sporozoites in salivary glands of
angiotensin I-, angiotensin II- or synthetic peptide-treated Ae.
aegypti. At day 7 post-infection 0.5 ml of ang II at 5 mM, 30 mM,
40 mM, 50 mM, 60 mM or PBS (control) were injected intratho-
racically in anesthetized Ae.aegypti. Salivary glands were dissected
24 hours after the microinjection and sporozoites counted. Mann-
Whitney tests indicated significant effects (p,0.0001) of the
peptides in the number of salivary glands sporozoites at 60 mM
concentration.
Found at: doi:10.1371/journal.pone.0003296.s002 (0.48 MB TIF)
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